Kiora Pharmaceuticals Inc (KPRX) stock
KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
$0.93−0.05 (-5.30%)
Close on Nov 17, 2026Market cap $4.11MP/E –Yield –
Kiora Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Kiora Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$12.83M. For fiscal 2025 it was -$12.83M, down 384.5% from the year before. The highest annual figure on record is $4.51M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.83M | -384.5% |
| FY2024 | Dec 31, 2024 | $4.51M | – |
| FY2023 | Dec 31, 2023 | -$12.59M | – |
| FY2022 | Dec 31, 2022 | -$12.31M | – |
| FY2021 | Dec 31, 2021 | -$14.24M | – |
| FY2020 | Dec 31, 2020 | -$6.87M | – |
| FY2018 | Dec 31, 2018 | -$10.84M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$794.44K | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.33M | -117.6% |
| Q4 FY2024 | Dec 31, 2024 | -$2.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.54M | – |
| Q1 FY2024 | Mar 31, 2024 | $13.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.92M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.63M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.70M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.57M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.37M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.04M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.01M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.72M | -307.7% |
| Q1 FY2020 | Mar 31, 2020 | -$1.97M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.87M | – |
| Q1 FY2019 | Mar 31, 2019 | $828.64K | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.49M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.18M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.80M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.38M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.14M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.33M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.92M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.38M | – |
See a number that looks wrong?